Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Are ACURA PHARMACEUTICALS (OTC:ACUR) retail investors starting to panic?
By Raphi Shpitalnik | Macroaxis Story |
It seems ACURA PHARMACEUTICALS may not recover as fast as we have hopped for as its price went down 25% today. ACURA PHARMACEUTICALS INC's current daily volatility is 10.01 percent, with a beta of 0.0 and an alpha of 0.33 over DOW. As many baby boomers are still indifferent towards current volatility, ACURA PHARMACEUTICALS INC. Why are we still confident in our projection for a recovery.
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Ellen Johnson
ACURA PHARMACEUTICALS INC currently holds roughly 493 K in cash with (117 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02. We provide trade advice to complement the prevailing expert consensus on ACURA PHARMACEUTICALS INC. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available today.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Acura Pharmaceuticals. Your research has to be compared to or analyzed against Acura Pharmaceuticals' peers to derive any actionable benefits. When done correctly, Acura Pharmaceuticals' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Acura Pharmaceuticals.
Investing in Acura Pharmaceuticals, just like investing in any other equity instrument, is characterized by a strong risk-return correlation. High risks mean high returns and low risk means lower expected returns. Risk management is the act of identifying and assessing the potential risk and developing strategies to minimize these risks and earn maximum possible profits while holding Acura Pharmaceuticals along with other instruments in the same portfolio. Using conventional technical analysis and fundamental analysis to select individual securities into a portfolio complements risk management and adds value to overall investors' investing strategies.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Acura Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Acura Pharmaceuticals in the context of predictive analytics.
Watch out for price decline
Please consider monitoring Acura Pharmaceuticals on a daily basis if you are holding a position in it. Acura Pharmaceuticals is trading at a penny-stock level, and the possibility of delisting is much higher compared to other otcs. However, just because the otc stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Acura Pharmaceuticals stock to be traded above the $1 level to remain listed. If Acura Pharmaceuticals otc stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How important is Acura Pharmaceuticals's Liquidity
Acura Pharmaceuticals financial leverage refers to using borrowed capital as a funding source to finance Acura Pharmaceuticals ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Acura Pharmaceuticals financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Acura Pharmaceuticals' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Acura Pharmaceuticals' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Acura Pharmaceuticals's total debt and its cash.
Acura Pharmaceuticals Correlation with Peers
Investors in Acura can reduce exposure to individual asset risk by holding a diversified portfolio of assets in addition to a long position in Acura Pharmaceuticals. Diversification will allow for the same portfolio return with reduced risk. The correlation table of Acura Pharmaceuticals and its peers is a two-dimensional matrix that shows the correlation coefficient between pairs of securities Acura is related in some way. The cells in the table are color-coded to highlight significantly positive and negative relationships. Each cell shows the correlation between one pair of equities and can be used to run pair trading strategies or create efficient portfolios with your current brokerage. Please check volatility of Acura for more details
Detailed Outlook On Acura Pharmaceuticals
ACURA PHARMACEUTICALS appears to be abnormally volatile, given 1 month investment horizon. ACURA PHARMACEUTICALS INC secures Sharpe Ratio (or Efficiency) of 0.0297, which signifies that the company had 0.0297% of return per unit of volatility over the last month. Our viewpoint regarding foreseeing the volatility of a stock is to use all available market data together with stock specific technical indicators that cannot be diversified away. We have found twenty-one technical indicators for ACURA PHARMACEUTICALS INC, which you can use to evaluate future volatility of the entity. Please makes use of ACURA PHARMACEUTICALS INC Coefficient Of Variation of 3039.29, market risk adjusted performance of 114.65, and Mean Deviation of 7.34 to double-check if our risk estimates are consistent with your expectations.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Acura Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.